Placental growth factor (PLGF)-based testing is a new blood test providing information on placental biomarkers which, when used alongside other diagnostic and clinical information, can help clinicians to predict, diagnose and appropriately manage potential pre-eclampsia. Pre-eclampsia being a multisystem hypertensive disorder of pregnancy, thought to be related to the development of the placenta.

What are the patient benefits?

  • Reassurance to pregnant women with hypertension

  • Reduction in the need for unnecessary hospitalisation

  • Increased clinical confidence in treatment plans

  • Avoidance of emergency medical interventions

  • Improved risk assessment to enable early planning for a safe birth

  • Facilitation of shared decision making

How is this being implemented in Dorset

  • A case study summarising implementation of PLGF testing at University Hospitals Dorset was original published in September 2022. This case study was updated in December 2024 to include additional clinical audit data and conclusions from a benefits realisation review. This updated (Dec 2024) case study is available here.